Axsome Therapeutics advances with new epilepsy treatment and Alzheimer's drug review

Axsome Therapeutics has reported strong financial growth alongside key pipeline developments. The company's latest updates include a news epilepsy treatment in its portfolio and a priority review for an Alzheimer's-related drug. Recent revenue increases and cost reductions have also strengthened its position in the market.

The US Food and Drug Administration (FDA) has granted a priority review for Auvelity's supplemental New Drug Application (sNDA). This filing targets agitation in Alzheimer's disease patients, with a decision expected by April 30. Meanwhile, the company has expanded its sales team and improved payer access for Auvelity and Cymbravo, boosting launch readiness.

Revenue growth has surged into double digits, driven by rising prescription volumes for existing products like Sunosi. The company's net loss has also shrunk compared to the previous year, reflecting tighter financial management. Current cash reserves are projected to cover operations until the business reaches cash flow positivity under its existing plan.

Axsome has added AXS-17, a news epilepsy treatment, to its development pipeline. Several Phase III trials and regulatory submissions are planned in the near future, further expanding its therapeutic offerings.

The FDA's priority review for Auvelity and the addition of AXS-17 mark significant steps in Axsome's pipeline expansion. With strong revenue growth, reduced losses, and ongoing launch preparations, the company is positioning itself for continued progress in neurology and psychiatry treatments. Current funding is expected to sustain operations until profitability is achieved.